Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
Billing and coding article A56071: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56071 (Billing and Coding: In Vitro Chemosensitivity & Chemoresistance Assays) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A56071: Billing and Coding: In Vitro Chemosensitivity & Chemoresistance Assays (Billing and Coding, effective 2025-10-16)
- Covered ICD-10-CM codes
- 0
- 0 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 3
- Full article
- cms.gov record
Procedure codes: 0083U, 84999, 89240.
Coverage indications, limitations and medical necessity
This is a noncoverage policy for the chemosensitivity and chemoresistance assays (CSRAs).
Summary of evidence (opening)
Chemosensitivity and Chemoresistance Assays (CSRAs)
In order to avoid ineffective chemotherapy toxicity, the intent of CSRAs is to assist oncologists with the selection of chemotherapy drugs at initial diagnosis and tumor recurrence.
Chemosensitivity Assays
A chemotherapy sensitivity assay determines if a tumor growth is inhibited by a known chemotherapy drug or drug combination. Thus, the intent of the chemosensitivity assay is to assist the oncologist with effective chemotherapy agent selection.
the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2018-10-01
- Current revision effective
- 2025-10-16
- Last reviewed by the contractor
- 2021-03-02
- MCD version
- 24
The contractor lists one National Coverage Determination as related: NCD 190.7 Human Tumor Stem Cell Drug Sensitivity Assays. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.
Other related documents: A56076 (Response to Comments), A56077 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Noridian Healthcare Solutions, LLC hub lists every other active policy from the same contractor.
The same policy title at other contractors
Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L37628 cover?
This is a noncoverage policy for the chemosensitivity and chemoresistance assays (CSRAs). The full 12-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L37628 apply to?
Noridian Healthcare Solutions, LLC applies it to Medicare claims in 13 states plus 3 territories: AK, AS, AZ, CA, GU, HI, ID, MP, MT, ND, NV, OR, SD, UT, WA, WY. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L37628?
The current export links no billing and coding article with a diagnosis list to LCD L37628, so Noridian Healthcare Solutions, LLC decides coverage on the 12-word policy text and the documentation in the record rather than by an automated diagnosis edit.
How do I appeal a denial under LCD L37628?
A denial under LCD L37628 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications, then file a redetermination with Noridian Healthcare Solutions, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.